title: [Prevalence and genotype distribution changes in hepatitis C virus co-infection among human immunodeficiency virus-infected patients].
abstract: BACKGROUND
  The prevalence of hepatitisC is decreasing among new diagnoses of HIV/HCV coinfection in Spain. The increasing use of the HCV treatment could have changed the HCV genotype distribution. The aim of this study is to analyze changes in the prevalence of HCV coinfection and in HCV genotype distribution among HIV-infected patients.
  
  
  METHODS
  A serial cross-sectional study was conducted that included all HIV-infected patients who attended the Outpatient Clinic of a hospital in Andalusia, between September 2008 and February 2009 (first period), and between January 2013 and June 2013 (second period).
  
  
  RESULTS
  A total of 520 and 651 patients were included in the first and second period, respectively. The risk factors of HCV infection in the first vs. second period were: IDU, 319 (61%) vs. 348 (53%); heterosexual contact, 111 (21%) vs. 135 (21%); homosexual men, 76 (15%) vs. 114 (22%) (P=.006). The prevalence of HCV antibody per period was: 358 (69%) vs. 380 (58%) (P=<.001), and for the HCV-RNA was 255 (49%) vs. 240 (37%) (P=<.001). In both periods, the HCV genotype distribution was: 1, 137 (60%) vs. 138 (59%); 3, 45 (20%) vs. 42 (18%); 4, 42 (18%) vs. 47 (20%) (P=.881).
  
  
  CONCLUSIONS
  The prevalence of HCV infection in HIV-infected patients has decreased in our area, including overall exposure to HCV virus and active infection during the last 5 years. However, the HCV genotype distribution has not changed.
authors.affiliation: Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España.
authors.forename: Celia
authors.initials: C
authors.lastname: Cifuentes
authors.affiliation: Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España.
authors.forename: María
authors.initials: M
authors.lastname: Mancebo-Hernández
authors.affiliation: Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España.
authors.forename: Elisabet
authors.initials: E
authors.lastname: Pérez-Navarro
authors.affiliation: Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España.
authors.forename: Eva
authors.initials: E
authors.lastname: Recio
authors.affiliation: Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España.
authors.forename: Patricia
authors.initials: P
authors.lastname: Monje-Agudo
authors.affiliation: Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España; Unidad Clínica Intercentros de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Macarena, Sevilla, España.
authors.forename: Adoración
authors.initials: A
authors.lastname: Valiente
authors.affiliation: Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España. Electronic address: japineda@telefonica.net.
authors.forename: Juan A
authors.initials: JA
authors.lastname: Pineda
mesh_terms: D000328:Adult; D060085:Coinfection; D003430:Cross-Sectional Studies; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology / Q000821:virology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence
keywords: Adicción a drogas por vía parenteral; Antivirales de acción directa; Direct-acting antiviral agents; Genotipo del virus de la hepatitis C; Hepatitis C virus; Hepatitis C virus genotype; Human immunodeficiency virus; Injecting drug use; Interferon; Interferón; Ribavirin; Ribavirina; Virus de la hepatitis C; Virus de la inmunodeficiencia humana